Please Wait.....
Report
Human Papillomavirus Vaccine Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027 Segmented By Valence (Bivalent, Quadrivalent, Nonvalent, Others), By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others), By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others), By Company and By Region
Market Report I 2022-12-01 I 113 Pages I TechSci Research
The global human papillomavirus vaccine market is anticipated to observe impressive growth during the forecast period, 2023-2027. The major factors include growing incidences of HPV-related diseases, and rise in initiatives by government and private organizations, which are curbing the growth of the market. Human papillomavirus infection is the most common sexually transmitted contamination caused by HPV-related cancers such as cervical, penile, and genital cancer. Human papillomavirus vaccines are immunizations that protects from certain type of human papillomavirus. It protects against either two, four or nine kinds of HPV. The other factors supporting the market's growth are, the increasing research for therapeutic vaccine, large number of clinical trials, increasing awareness and government investments, ease in approval of new HPV vaccines, and growing need to reduce HPV infections.
Increasing cases of Human Papillomavirus Diseases among the Population
Upsurge in the cases of HPV related diseases such as anal, oropharynx, and genital parts and growing demand for HPV vaccines, are projecting to propel the growth of the market, globally. There are just three types of vaccines in the market: bivalent, tetravalent, and nonavalent. All the three vaccines are highly effective in avoiding infection with both virus types 16 and 18, which are liable for curing 70% of cervical cancer cases. According to the Centers for Disease Control and Prevention (CDC), in U.S, human papillomavirus is the most common sexually transmitted infection. Over 70% of vulvar and vaginal diseases, 60% of penile malignant growths, and 90% of anal cancer and cervical tumors are caused because of HPV. Moreover, in women, cervical cancer is very common among age between 9 to 30, which spur the need for HPV vaccine. For instance, according to the WHO, in 2017, cervical cancer is liable for over 2,50,000 deaths of women globally and 85% of these deaths occur in developing countries.
Increasing Initiatives by Government & Private Organizations
Over the past few years, governments of different nations and private organizations are taking several steps to bolster the growth of the market. Rising initiatives such as heavy investments on research and development, increase in awareness programs, extensive research actives and clinical trials and ease in approvals by the regulatory bodies, are the supporting factors for the market. For instance, recently, India launched the first quadrivalent human papillomavirus vaccine (qHPV) against cervical cancer. Also, Profectus Biosciences, Inc., is in process to develop GeneVax prime/VesiculoVax, a therapeutic vaccine for HPV. The vaccine is believed to be effective against seven HPV kinds. Furthermore, organizations, especially UNICEF, have made efforts to improve vaccine acceptance over the years. The impact of the Pan American Health Organization (PAHO) revolving fund and UNICEF supply division permits vaccinations to be acquired at lower prices for diverse nations.
Market Segmentation
The global human papillomavirus vaccine market is segmented into valence, disease indication, distribution channel, and company. Based on valence, the market is divided into bivalent, quadrivalent, nonvalent, and others. Based on disease indication, the market is divided into cervical cancer, anal cancer, vaginal cancer, penile cancer, vulvar cancer, and others. Based on distribution channel, the market is segmented into hospitals & clinics, governmental & non-governmental organizations, public & private alliances, and others. In terms of country, the United States is expected to be a lucrative market in the forecast period due to rising prevalence of HPV-related diseases and better healthcare infrastructure in the country.
Market Players
Serum Institute of India Pvt. Ltd., GlaxoSmithKline Plc., Johnson & Johnson, Merck & Co., Inc., AstraZeneca Plc, Novartis AG, Inovio Pharmaceuticals, Inc., Xenetic Biosciences, Inc., Sanofi SA, and Bharat Biotech International Limited are some of the leading companies operating in the market.
Report Scope:
In this report, global human papillomavirus vaccine market has been segmented into following categories, in addition to the industry trends which have also been detailed below:
- Human Papillomavirus Vaccine Market, By Valence:
o Bivalent
o Quadrivalent
o Nonvalent
o Others
- Human Papillomavirus Vaccine Market, By Disease Indication:
o Cervical Cancer
o Anal Cancer
o Vaginal Cancer
o Penile Cancer
o Vulvar Cancer
o Others
- Human Papillomavirus Vaccine Market, By Distribution Channel:
o Hospitals & Clinics
o Governmental & Non-Governmental Organizations
o Public & Private Alliances
o Others
- Human Papillomavirus Vaccine Market, By Region:
o North America
- United States
- Canada
- Mexico
o Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
o Europe & CIS
- Germany
- France
- United Kingdom
- Spain
- Italy
o South America
- Brazil
- Argentina
- Colombia
o Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in Human Papillomavirus Vaccine Market
Available Customizations:
With the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
- Detailed analysis and profiling of additional market players (up to five).
1. Product Overview
2. Research Methodology
3. Impact of COVID-19 on Global Human Papillomavirus Vaccine Market
4. Voice of Customer
5. Executive Summary
6. Clinical Trial Analysis
7. Patent Analysis
8. Global Human Papillomavirus Vaccine Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Valence (Bivalent, Quadrivalent, Nonvalent, Others)
8.2.2. By Disease Indication (Cervical Cancer, Anal Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Others)
8.2.3. By Distribution Channel (Hospitals & Clinics, Governmental & Non-Governmental Organizations, Public & Private Alliances, Others)
8.2.4. By Company (2021)
8.2.5. By Region
8.3. Market Map
9. North America Human Papillomavirus Vaccine Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Valence
9.2.2. By Disease Indication
9.2.3. By Distribution Channel
9.2.4. By Country
9.3. North America: Country Analysis
9.3.1. United States Human Papillomavirus Vaccine Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Valence
9.3.1.2.2. By Disease Indication
9.3.1.2.3. By Distribution Channel
9.3.2. Mexico Human Papillomavirus Vaccine Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Valence
9.3.2.2.2. By Disease Indication
9.3.2.2.3. By Distribution Channel
9.3.3. Canada Human Papillomavirus Vaccine Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Valence
9.3.3.2.2. By Disease Indication
9.3.3.2.3. By Distribution Channel
10. Europe Human Papillomavirus Vaccine Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Valence
10.2.2. By Disease Indication
10.2.3. By Distribution Channel
10.2.4. By Country
10.3. Europe: Country Analysis
10.3.1. France Human Papillomavirus Vaccine Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Valence
10.3.1.2.2. By Disease Indication
10.3.1.2.3. By Distribution Channel
10.3.2. Germany Human Papillomavirus Vaccine Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Valence
10.3.2.2.2. By Disease Indication
10.3.2.2.3. By Distribution Channel
10.3.3. United Kingdom Human Papillomavirus Vaccine Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Valence
10.3.3.2.2. By Disease Indication
10.3.3.2.3. By Distribution Channel
10.3.4. Italy Human Papillomavirus Vaccine Market Outlook
10.3.4.1. Market Size & Forecast
10.3.4.1.1. By Value
10.3.4.2. Market Share & Forecast
10.3.4.2.1. By Valence
10.3.4.2.2. By Disease Indication
10.3.4.2.3. By Distribution Channel
10.3.5. Spain Human Papillomavirus Vaccine Market Outlook
10.3.5.1. Market Size & Forecast
10.3.5.1.1. By Value
10.3.5.2. Market Share & Forecast
10.3.5.2.1. By Valence
10.3.5.2.2. By Disease Indication
10.3.5.2.3. By Distribution Channel
11. Asia-Pacific Human Papillomavirus Vaccine Market Outlook
11.1. Market Size & Forecast
11.1.1. By Value
11.2. Market Share & Forecast
11.2.1. By Valence
11.2.2. By Disease Indication
11.2.3. By Distribution Channel
11.2.4. By Country
11.3. Asia-Pacific: Country Analysis
11.3.1. China Human Papillomavirus Vaccine Market Outlook
11.3.1.1. Market Size & Forecast
11.3.1.1.1. By Value
11.3.1.2. Market Share & Forecast
11.3.1.2.1. By Valence
11.3.1.2.2. By Disease Indication
11.3.1.2.3. By Distribution Channel
11.3.2. India Human Papillomavirus Vaccine Market Outlook
11.3.2.1. Market Size & Forecast
11.3.2.1.1. By Value
11.3.2.2. Market Share & Forecast
11.3.2.2.1. By Valence
11.3.2.2.2. By Disease Indication
11.3.2.2.3. By Distribution Channel
11.3.3. Japan Human Papillomavirus Vaccine Market Outlook
11.3.3.1. Market Size & Forecast
11.3.3.1.1. By Value
11.3.3.2. Market Share & Forecast
11.3.3.2.1. By Valence
11.3.3.2.2. By Disease Indication
11.3.3.2.3. By Distribution Channel
11.3.4. South Korea Human Papillomavirus Vaccine Market Outlook
11.3.4.1. Market Size & Forecast
11.3.4.1.1. By Value
11.3.4.2. Market Share & Forecast
11.3.4.2.1. By Valence
11.3.4.2.2. By Disease Indication
11.3.4.2.3. By Distribution Channel
11.3.5. Australia Human Papillomavirus Vaccine Market Outlook
11.3.5.1. Market Size & Forecast
11.3.5.1.1. By Value
11.3.5.2. Market Share & Forecast
11.3.5.2.1. By Valence
11.3.5.2.2. By Disease Indication
11.3.5.2.3. By Distribution Channel
12. South America Human Papillomavirus Vaccine Market Outlook
12.1. Market Size & Forecast
12.1.1. By Value
12.2. Market Share & Forecast
12.2.1. By Valence
12.2.2. By Disease Indication
12.2.3. By Distribution Channel
12.2.4. By Country
12.3. South America: Country Analysis
12.3.1. Brazil Human Papillomavirus Vaccine Market Outlook
12.3.1.1. Market Size & Forecast
12.3.1.1.1. By Value
12.3.1.2. Market Share & Forecast
12.3.1.2.1. By Valence
12.3.1.2.2. By Disease Indication
12.3.1.2.3. By Distribution Channel
12.3.2. Argentina Human Papillomavirus Vaccine Market Outlook
12.3.2.1. Market Size & Forecast
12.3.2.1.1. By Value
12.3.2.2. Market Share & Forecast
12.3.2.2.1. By Valence
12.3.2.2.2. By Disease Indication
12.3.2.2.3. By Distribution Channel
12.3.3. Colombia Human Papillomavirus Vaccine Market Outlook
12.3.3.1. Market Size & Forecast
12.3.3.1.1. By Value
12.3.3.2. Market Share & Forecast
12.3.3.2.1. By Valence
12.3.3.2.2. By Disease Indication
12.3.3.2.3. By Distribution Channel
13. Middle East and Africa Human Papillomavirus Vaccine Market Outlook
13.1. Market Size & Forecast
13.1.1. By Value
13.2. Market Share & Forecast
13.2.1. By Valence
13.2.2. By Disease Indication
13.2.3. By Distribution Channel
13.2.4. By Country
13.3. MEA: Country Analysis
13.3.1. South Africa Human Papillomavirus Vaccine Market Outlook
13.3.1.1. Market Size & Forecast
13.3.1.1.1. By Value
13.3.1.2. Market Share & Forecast
13.3.1.2.1. By Valence
13.3.1.2.2. By Disease Indication
13.3.1.2.3. By Distribution Channel
13.3.2. Saudi Arabia Human Papillomavirus Vaccine Market Outlook
13.3.2.1. Market Size & Forecast
13.3.2.1.1. By Value
13.3.2.2. Market Share & Forecast
13.3.2.2.1. By Valence
13.3.2.2.2. By Disease Indication
13.3.2.2.3. By Distribution Channel
13.3.3. UAE Human Papillomavirus Vaccine Market Outlook
13.3.3.1. Market Size & Forecast
13.3.3.1.1. By Value
13.3.3.2. Market Share & Forecast
13.3.3.2.1. By Valence
13.3.3.2.2. By Disease Indication
13.3.3.2.3. By Distribution Channel
14. Market Dynamics
14.1. Drivers
14.2. Challenges
15. Market Trends & Developments
16. Competitive Landscape
16.1. Serum Institute of India Pvt. Ltd.
16.2. GlaxoSmithKline Plc.
16.3. Johnson & Johnson
16.4. Merck & Co., Inc.
16.5. AstraZeneca Plc
16.6. Novartis AG
16.7. Inovio Pharmaceuticals, Inc.
16.8. Xenetic Biosciences, Inc.
16.9. Sanofi SA
16.10. Bharat Biotech International Limited
17. Strategic Recommendations
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security